Trial Profile

An Open-label, Non-randomized Study to Investigate the Effects of Twice-Daily Milvexian Administration on the Pharmacokinetics of Single Doses of Midazolam, Ethinylestradiol and Drospirenone in Healthy Adult Females

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Milvexian (Primary) ; Drospirenone; Ethinylestradiol; Midazolam
Indications Acute coronary syndromes; Atrial fibrillation; Stroke; Thrombosis; Venous thromboembolism
Focus Pharmacokinetics
Sponsors Janssen Pharmaceutica

16 Aug 2023 Status changed from active, no longer recruiting to completed.
28 Jun 2023 Status changed from recruiting to active, no longer recruiting.
07 Feb 2023 Planned primary completion date changed from 28 Jun 2023 to 20 Jul 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com